KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Non-cash Items: 2010-2018

  • Alnylam Pharmaceuticals' Non-cash Items fell 99.06% to $5.7 million in Q4 2018 from the same period last year, while for Dec 2018 it was $5.7 million, marking a year-over-year decrease of 99.06%. This contributed to the annual value of $5.7 million for FY2018, which is 8.31% up from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Non-cash Items of $5.7 million as of Q4 2018, which was down 99.06% from $609.6 million recorded in Q4 2017.
  • Alnylam Pharmaceuticals' Non-cash Items' 5-year high stood at $609.6 million during Q4 2017, with a 5-year trough of $4.7 million in Q4 2015.
  • For the 2-year period, Alnylam Pharmaceuticals' Non-cash Items averaged around $307.7 million, with its median value being $307.7 million (2017).
  • Data for Alnylam Pharmaceuticals' Non-cash Items shows a maximum YoY slumped of 99.06% (in 2018) over the last 5 years.
  • Quarterly analysis of 4 years shows Alnylam Pharmaceuticals' Non-cash Items stood at $4.7 million in 2014, then dropped by 0.78% to $4.7 million in 2015, then reached $609.6 million in 2017, then tumbled by 99.06% to $5.7 million in 2018.
  • Its Non-cash Items stands at $5.7 million for Q4 2018, versus $609.6 million for Q4 2017 and $4.7 million for Q4 2015.